|
|
Volumn 9, Issue 6, 2003, Pages 544-551
|
|
Determinants of the cost-effectiveness of statins.
a
a
SCRIBCO
(United States)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
LOW DENSITY LIPOPROTEIN CHOLESTEROL;
BLOOD;
CLINICAL PROTOCOL;
CLINICAL TRIAL;
COST BENEFIT ANALYSIS;
ECONOMICS;
FEMALE;
HEALTH INSURANCE;
HUMAN;
HYPERCHOLESTEROLEMIA;
MALE;
MORTALITY;
REVIEW;
RISK FACTOR;
CHOLESTEROL, LDL;
CLINICAL PROTOCOLS;
CLINICAL TRIALS;
COST-BENEFIT ANALYSIS;
FEMALE;
HUMANS;
HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;
HYPERCHOLESTEROLEMIA;
MALE;
MANAGED CARE PROGRAMS;
RISK FACTORS;
|
|
EID: 1542437305
PISSN: 10834087
EISSN: None
Source Type: Journal
DOI: 10.18553/jmcp.2003.9.6.544 Document Type: Review |
|
Times cited : (31)
|
|
References (45)
|
